



Sotagliflozin

Catalog No: tcsc1069

Available Sizes
Size: 5mg
Size: 10mg
Size: 25mg
Size: 50mg
Specifications
CAS No: 1018899-04-1
Formula: C ₂₁ H ₂₅ ClO ₅ S
Pathway: Membrane Transporter/Ion Channel
Target: SGLT
Purity / Grade: >98%
Solubility: 10 mM in DMSO
Alternative Names: LX-4211;LP-802034
Observed Molecular Weight: 424.94





Product Description

Sotagliflozin (LX-4211) is a potent dual SGLT2/1 inhibitor. Antidiabetic agents.

IC50 & Target: SGLT1/2

In Vitro: LX4211 enhanced urinary glucose excretion by inhibiting SGLT2-mediated renal glucose reabsorption; markedly and significantly improved multiple measures of glycemic control, including fasting plasma glucose, oral glucose tolerance, and HbA(1c); and significantly lowered serum triglycerides. LX4211 also mediated trends for lower weight, lower blood pressure, and higher glucagon-like peptide-1 levels. In a follow-up single-dose study in 12 patients with T2DM, LX4211 (300 mg) significantly increased glucagon-like peptide-1 and peptide YY levels relative to pretreatment values, probably by delaying SGLT1-mediated intestinal glucose absorption [1]. LX4211-treated mice and SGLT1-/- mice also had increased GLP-1 AUC values, decreased glucose-dependent insulinotropic polypeptide (GIP) AUC values, and decreased blood glucose excursions during the 6 hours after a challenge with oral glucose alone [2].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!